论文部分内容阅读
目的观察高频热疗联合吉西他滨单药化疗治疗老年中晚期非小细胞肺癌的近期疗效、生存率、毒副作用及临床受益情况。方法将2003年2月至2006年12月间共80例老年中晚期非小细胞肺癌患者随机分入观察组和对照组。观察组(40例)采用高频热疗联合吉西他滨单药化疗,共4个周期,治疗结束后1个月评价疗效及毒副作用;对照组(40例)采用吉西他滨联合顺铂化疗,共4个周期,治疗结束后1个月评价疗效及毒副作用。然后对两组患者进行随访,统计生存率并进行比较。结果观察组与对照组比较,近期疗效差异无显著性,临床受益率明显提高,毒副作用减少,1,2年生存率差异无显著性。结论高频热疗联合吉西他滨单药化疗治疗老年中晚期非小细胞肺癌疗效确切,临床受益率明显提高,毒副作用可耐受。
Objective To observe the short-term effect, survival rate, side effects and clinical benefit of high-frequency hyperthermia combined with gemcitabine monotherapy in the treatment of advanced non-small cell lung cancer in elderly. Methods A total of 80 elderly patients with advanced non-small cell lung cancer from February 2003 to December 2006 were randomly divided into observation group and control group. The observation group (40 cases) was treated with high-frequency hyperthermia combined with gemcitabine monotherapy for 4 cycles. One month after the end of treatment, the curative effect and side effects were evaluated. In the control group (40 cases), gemcitabine combined with cisplatin Cycle, 1 month after the treatment evaluation efficacy and side effects. Then two groups of patients were followed up, the survival rate was compared and compared. Results Compared with the control group, there was no significant difference in the short-term curative effect between the observation group and the control group, the clinical benefit rate was significantly increased, the toxic and side effects were decreased, and there was no significant difference in the 1- and 2-year survival rates. Conclusion High-frequency hyperthermia combined with gemcitabine monotherapy for the treatment of advanced non-small cell lung cancer is effective, the clinical benefit rate was significantly improved, the toxic side effects can be tolerated.